Data gathered: October 8
AI Stock Analysis - Arcutis Biotherapeutics (ARQT)
Analysis generated September 13, 2025. Powered by Chat GPT.
Arcutis Biotherapeutics, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Their primary products address conditions such as eczema, psoriasis, and vitiligo. Arcutis has shown promise in its research and development pipeline, aiming to bring innovative solutions to market where there is significant unmet medical need.
Stock Alerts - Arcutis Biotherapeutics (ARQT)
 |
Arcutis Biotherapeutics | October 7 Insider Alert: Edwards Larry Todd is selling shares |
|
Arcutis Biotherapeutics | October 7 Employee Rating is down by 13.6% over the last month. |
|
Arcutis Biotherapeutics | October 4 Insider Alert: Watanabe Todd is selling shares |
|
Arcutis Biotherapeutics | October 3 Price is down by -6.3% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Arcutis Biotherapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 5 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 22,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | 36 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 32 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,516 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 46 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,448 | Sign up | Sign up | Sign up |
| Twitter Followers | 610 | Sign up | Sign up | Sign up |
| Twitter Mentions | 16 | Sign up | Sign up | Sign up |
| X Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 48 | Sign up | Sign up | Sign up |
| Linkedin Employees | 378 | Sign up | Sign up | Sign up |
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
| Price | $21.24 |
| Target Price | Sign up |
| Volume | 2,470,000 |
| Market Cap | $2.37B |
| Year Range | $11.4 - $21.25 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Earnings Date | October 28 '25 |
| Industry | Biotechnology |
In the news
 |
Arcutis Biotherapeutics announces FDA approval of ZORYVE cream sNDAOctober 6 - Thefly.com |
 |
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 3.2% After Insider SellingOctober 4 - ETF Daily News |
 |
Arcutis Biotherapeutics (ARQT): Evaluating Valuation as Upward Earnings Revisions Fuel Renewed Investor InterestOctober 4 - Yahoo Entertainment |
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 3 - GlobeNewswire |
|
 |
Financial Survey: Arcutis Biotherapeutics (NASDAQ:ARQT) vs. BioMarin Pharmaceutical (NASDAQ:BMRN)October 2 - ETF Daily News |
 |
Arcutis Biotherapeutics, Inc. (ARQT) Hit a 52 Week High, Can the Run Continue?September 30 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 82M | 7.5M | 74M | -16M | -12M | -0.130 |
| Q1 '25 | 66M | 8.8M | 57M | -25M | -19M | -0.200 |
| Q4 '24 | 71M | 6.9M | 64M | -11M | -4.5M | -0.090 |
| Q3 '24 | 45M | 5.5M | 39M | -42M | -33M | -0.330 |
| Q2 '24 | 31M | 3.5M | 27M | -52M | -44M | -0.420 |
Insider Transactions View All
| Edwards Larry Todd filed to sell 179,324 shares at $20.8. October 6 '25 |
| Edwards Larry Todd filed to sell 178,897 shares at $20. October 6 '25 |
| Watanabe Todd filed to sell 846,440 shares at $20. October 3 '25 |
| Welgus Howard G. filed to sell 99,744 shares at $18.9. October 3 '25 |
| Welgus Howard G. filed to sell 100,206 shares at $18.9. October 3 '25 |
Similar companies
Read more about Arcutis Biotherapeutics (ARQT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Arcutis Biotherapeutics?
The Market Cap of Arcutis Biotherapeutics is $2.37B.
When does Arcutis Biotherapeutics report earnings?
Arcutis Biotherapeutics will report its next earnings on October 28 '25.
What is the current stock price of Arcutis Biotherapeutics?
Currently, the price of one share of Arcutis Biotherapeutics stock is $21.24.
How can I analyze the ARQT stock price chart for investment decisions?
The ARQT stock price chart above provides a comprehensive visual representation of Arcutis Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Arcutis Biotherapeutics shares. Our platform offers an up-to-date ARQT stock price chart, along with technical data analysis and alternative data insights.
Does ARQT offer dividends to its shareholders?
As of our latest update, Arcutis Biotherapeutics (ARQT) does not offer dividends to its shareholders. Investors interested in Arcutis Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Arcutis Biotherapeutics?
Some of the similar stocks of Arcutis Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
